How Pharmx’s New Portals Could Reshape Pharmacy Tech Growth
Pharmx Technologies Limited reported a 13% increase in revenue for FY25, driven by expanded supplier-pharmacy connections and Marketplace platform growth, while profit before tax declined due to significant investments in new technology platforms.
- 13% revenue growth to $7.53 million in FY25
- Profit before tax fell to $79,000 amid increased tech and marketing spend
- Launch of Supplier and Pharmacy Portals enhances platform capabilities
- Operating cash flow impacted by $9.9 million court case payment
- Board strengthened with appointment of alternate non-executive director
Strong Revenue Growth Despite Profit Pressure
Pharmx Technologies Limited has delivered a solid 13% increase in revenue for the financial year ended 30 June 2025, reaching $7.53 million. This growth was primarily driven by an expansion in supplier-to-pharmacy connections and a near doubling of revenue from its Marketplace platform. The company’s fledgling data analytics business also contributed its first revenues, signaling early traction in this new segment.
Investing Heavily in a Unified Technology Platform
Despite the revenue gains, Pharmx’s profit before tax declined sharply to $79,000 from $581,000 the previous year. This contraction reflects deliberate strategic investments in technology, marketing, and personnel to support the rollout of a new single platform strategy. Key milestones included the successful launch of the Supplier Portal and the Pharmacy Portal in June 2025, both designed to streamline operations and deepen engagement across the pharmacy supply chain in Australia and New Zealand.
Cash Flow and Legal Settlement Impact
The company reported an operating cash outflow of $8.13 million, heavily influenced by a $9.9 million payment related to the resolution of a longstanding court case. Excluding this one-off outflow, underlying operating cash flow was positive, albeit lower than the prior year. Pharmx ended the year with $4.17 million in cash, maintaining a disciplined approach to balancing growth investments with financial prudence.
Board and Leadership Developments
Pharmx also strengthened its governance with the appointment of Sandy Mellis as an alternate non-executive director, bringing extensive experience in consumer health and beauty sectors. The leadership team continues to evolve, with a focus on building capabilities to support the company’s growth ambitions and technology innovation roadmap.
Looking Ahead, Growth and Innovation Focus
Looking forward, Pharmx plans to accelerate supplier onboarding, enhance AI-driven analytics, and expand its addressable market. The company remains committed to modernizing its platform infrastructure and leveraging digital tools to drive efficiency and deepen customer loyalty. While the Australian and New Zealand pharmacy markets offer attractive growth prospects, Pharmx acknowledges risks including customer concentration and cyber threats, which it aims to mitigate through robust governance and technology safeguards.
Bottom Line?
Pharmx’s FY25 results underscore a pivotal year of investment and platform transformation, setting the stage for growth but requiring close monitoring of returns and risks.
Questions in the middle?
- How quickly will Pharmx’s new portals drive sustained profitability?
- What is the company’s strategy to diversify its customer base and reduce concentration risk?
- How will Pharmx safeguard against evolving cyber threats given its critical role in pharmacy supply chains?
